Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 1:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 64 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ceftriaxone sodium Clear all
Terminated Phase 2 Interventional Results available

Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT)

NCT04999592
View directory record Official record
Conditions
Out-Of-Hospital Cardiac Arrest, Pneumonia
Interventions
Standard of care without prophylaxis, Antibiotic prophylaxis
Drug
Lead sponsor
David J. Gagnon
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 1, 2026, 1:34 AM EDT
Completed No phase listed Observational

Multi-Drug Resistant Organism (MDRO): Study of Highly Resistant Escherichia Coli

NCT04574596
View directory record Official record
Conditions
E Coli Infection
Interventions
no Intervention
Other
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
300 participants
Timeline
2020 – 2021
U.S. locations
13
States / cities
Torrance, California • Aurora, Colorado • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 1, 2026, 1:34 AM EDT
Terminated Not applicable Interventional Results available

Ceftriaxone in the Management of Bipolar Depression

NCT00566111
View directory record Official record
Conditions
Bipolar Depression
Interventions
ceftriaxone, Saline solution
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 1, 2026, 1:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)

NCT04870138
View directory record Official record
Conditions
Gonococcal Infection
Interventions
Azithromycin, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090 A26, Neisseria gonorrhoeae strain FA7527
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 35 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 1, 2026, 1:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Two Different Antibiotics Versus One Antibiotic for Pediatric Perforated Appendicitis

NCT03289351
View directory record Official record
Conditions
Perforated Appendicitis, Postoperative Infection
Interventions
Piperacillin, Tazobactam Drug Combination
Drug
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
Up to 18 Years
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
2
States / cities
Phoenix, Arizona • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Oct 1, 2026, 1:34 AM EDT
Terminated Phase 4 Interventional

Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens

NCT03560232
View directory record Official record
Conditions
Open Fracture, Post-Op Wound Infection
Interventions
Ceftriaxone, Ampicillin/sulbactam, Piperacillin/tazobactam, Cefazolin + Gentamicin, Clindamycin + Gentamicin
Drug
Lead sponsor
Mercy Health Ohio
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Warren, Ohio • Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 1, 2026, 1:34 AM EDT
Recruiting Phase 4 Interventional

Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP

NCT06494072
View directory record Official record
Conditions
Community Acquired Pneumonia in Children
Interventions
Ampicillin for Injection, Ceftriaxone for Injection, Amoxicillin, Ampicillin / Sulbactam Injection, Amoxicillin-clavulanate, Clindamycin, Cefprozil, Levofloxacin
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
3 Months to 18 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 1, 2026, 1:34 AM EDT
Not listed Phase 2 Interventional

Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.

NCT04869579
View directory record Official record
Conditions
Covid19
Interventions
Selenium (as Selenious Acid), Placebo
Drug · Other
Lead sponsor
CHRISTUS Health
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Longview, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 1, 2026, 1:34 AM EDT
Recruiting Not applicable Interventional

Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial

NCT06080698
View directory record Official record
Conditions
Gram-negative Bacteremia
Interventions
Intravenous Antibiotics, Oral Antibiotics
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 1, 2026, 1:34 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection

NCT01756924
View directory record Official record
Conditions
Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Infected Spacers
Interventions
CEM-102, IV or Oral standard of care antibiotics, Rifampin
Drug
Lead sponsor
Arrevus Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Sarasota, Florida • Tamarac, Florida • Savannah, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Oct 1, 2026, 1:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

NCT05294588
View directory record Official record
Conditions
Gonorrhea Male
Interventions
Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090, Meningococcal Group B Vaccine, Influenza Vaccine, Tetanus-diptheria Vaccine
Drug · Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 1, 2026, 1:34 AM EDT
Not yet recruiting Phase 4 Interventional

Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia

NCT07537413
View directory record Official record
Conditions
Community Acquired Pneumonia (CAP)
Interventions
Ceftriaxone 1 gram daily, Ceftriaxone 2 grams daily
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Baltimore, Maryland • Glen Burnie, Maryland • Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 1, 2026, 1:34 AM EDT
Recruiting Early Phase 1 Interventional

Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease

NCT06611111
View directory record Official record
Conditions
Post-Treatment Lyme Disease
Interventions
Ceftriaxone (Rocephin®), Dextrose 5% (D5W)
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
East Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 1, 2026, 1:34 AM EDT
Completed Phase 3 Interventional

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease

NCT00000938
View directory record Official record
Conditions
Lyme Disease
Interventions
ceftriaxone, doxycycline
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 1, 2026, 1:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL])

NCT02384200
View directory record Official record
Conditions
Nephrolithiasis, Urinary Tract Infections
Interventions
nitrofurantoin monohydrate/macrocrystalline capsules, ampicillin, gentamicin, vancomycin, ceftriaxone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
7
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2019 · Synced Oct 1, 2026, 1:34 AM EDT
Completed No phase listed Observational

Ceftriaxone and Jaundice in Neonates

NCT03133637
View directory record Official record
Conditions
Jaundice and Sepsis in Neonates
Interventions
ceftriaxone
Drug
Lead sponsor
University of Rochester
Other
Eligibility
3 Days to 7 Days
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 1, 2026, 1:34 AM EDT
Terminated Phase 4 Interventional Results available

Early Antibiotics After Aspiration in ICU Patients

NCT05079620
View directory record Official record
Conditions
Aspiration, Aspiration Pneumonia
Interventions
Ceftriaxone, Amoxicillin clavulanic acid, Cefepime, Vancomycin, Levofloxacin
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 1, 2026, 1:34 AM EDT
Terminated Phase 4 Interventional Results available

Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)

NCT05156437
View directory record Official record
Conditions
Endocarditis
Interventions
Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin, Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 1, 2026, 1:34 AM EDT
Completed Not applicable Interventional Results available

The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial

NCT02800785
View directory record Official record
Conditions
Appendicitis
Interventions
Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin, Appendectomy
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
1,552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
25
States / cities
Sylmar, California • Torrance, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 1, 2026, 1:34 AM EDT
Not listed Phase 4 Interventional

Antibiotics to Decrease Post ERCP Cholangitis

NCT03087656
View directory record Official record
Conditions
Cholangitis
Interventions
Ceftriaxone, Levofloxacin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 1, 2026, 1:34 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Ceftriaxone for Post-Treatment Lyme Disease

NCT06785402
View directory record Official record
Conditions
Post-Treatment Lyme Disease Syndrome
Interventions
Ceftriaxone treatment, Placebo
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 1, 2026, 1:34 AM EDT
Completed Phase 1 Interventional

VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy

NCT00004216
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
salmonella VNP20009, cefixime, ceftriaxone sodium, ciprofloxacin, trimethoprim-sulfamethoxazole
Biological · Drug
Lead sponsor
Vion Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts • Cleveland, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 1, 2026, 1:34 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 1, 2026, 1:34 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea

NCT02257918
View directory record Official record
Conditions
Gonorrhoea
Interventions
AZD0914, Ceftriaxone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Birmingham, Alabama • Indianapolis, Indiana • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 1, 2026, 1:34 AM EDT